Marketing-authorisation holder · United States
Emerge Bioscience Pte. Ltd.
5 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
5 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Garzulys300units/3ml (100units/ml) · Injection | Insulin aspart | United States | Marketed | 2026 |
| Garzulys1,000units/10ml (100units/ml) · Injection | Insulin aspart | United States | Marketed | 2026 |
| Yusimry40mg/0.4ml · Injection | Adalimumab | United States | Marketed | 2026 |
| Yusimry40mg/0.8ml · Injection | Adalimumab | United States | Marketed | 2023 |
| Yusimry80mg/0.8ml · Injection | Adalimumab | United States | Marketed | 2026 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 5 | 5 | 0 | CompaniesAll medicines |